Korean Medication Algorithm Project for Bipolar Disorder: third revision

Objective: To constitute the third revision of the guidelines for the treatment of bipolar disorder issued by the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP 2014).

Methods: A 56-item questionnaire was used to obtain the consensus of experts regarding pharmacological treatment strategies for the various phases of bipolar disorder and for special populations. The review committee included 110 Korean psychiatrists and 38 experts for child and adolescent psychiatry. Of the committee members, 64 general psychiatrists and 23 child and adolescent psychiatrists responded to the survey.

Results: The treatment of choice (TOC) for euphoric, mixed, and psychotic mania was the combination of a mood stabilizer (MS) and an atypical antipsychotic (AAP); the TOC for acute mild depression was monotherapy with MS or AAP; and the TOC for moderate or severe depression was MS plus AAP/antidepressant. The first-line maintenance treatment following mania or depression was MS monotherapy or MS plus AAP; the first-line treatment after mania was AAP monotherapy; and the first-line treatment after depression was lamotrigine (LTG) monotherapy, LTG plus MS/AAP, or MS plus AAP plus LTG. The first-line treatment strategy for mania in children and adolescents was MS plus AAP or AAP monotherapy. For geriatric bipolar patients, the TOC for mania was AAP/MS monotherapy, and the TOC for depression was AAP plus MS or AAP monotherapy.

Conclusion: The expert consensus in the KMAP-BP 2014 differed from that in previous publications; most notably, the preference for AAP was increased in the treatment of acute mania, depression, and maintenance treatment. There was increased expert preference for the use of AAP and LTG. The major limitation of the present study is that it was based on the consensus of Korean experts rather than on experimental evidence.

Keywords: pharmacological treatment, treatment guideline, expert consensus

Introduction

Recent advances in psychopharmacology and the development of novel psychotropic drugs have led to rapid changes in the pharmacological treatment strategies for bipolar disorder as well as the publication of various treatment algorithms and clinical practice guidelines.1-15 Because treatment strategies used for clinical practice vary widely from country to country due to diverse health insurance policies, economic situations, and ethnicities, several countries have initiated development of their own population-specific treatment guidelines. For example, the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) began in 2001, and the first set of guidelines, KMAP-BP 2002, was published 1 year later.16 Feasibility studies of the KMAP-BP 2002 showed that its algorithm could be successfully implemented in clinical settings in Korea.17-19 And based on continuing progress in psychopharmacology, the KMAP-BP was further revised in 200620 and 2010.21
Following the release of KMAP-BP 2010, novel clinical data and updated guidelines for the treatment of bipolar disorder became available, demonstrating that some medications were effective and some were not. Based on these studies, several medications were approved for the treatment of bipolar disorder, and various revised guidelines adopted these therapies as first-line or second-line options. Since 2010, further advances and novel findings have been reported and, thus, the Korean College of Neuropsychopharmacology and the Korean Society for Affective Disorders have undertaken a third revision of the KMAP-BP to reflect changes in expert opinion regarding the treatment of bipolar disorder. Here, an overview of the current consensus of Korean experts regarding pharmacological treatments for bipolar disorder is presented.

**Methods**

The detailed methods regarding the constitution of the review committee, preparation of the questionnaire, data analyses, and development of the treatment guidelines and algorithms were similar to those in previous KMAP-BP studies.

**Review committee**

The review committee included 110 Korean psychiatrists who were life members of the Korean Society for Affective Disorders, had more than 15 years of clinical experience in the field of mood disorders, and had published at least one paper regarding mood disorders during the last year. The committee members worked in a wide variety of clinical settings including university hospitals (n=73), general/psychiatric hospitals (n=24), and private psychiatric clinics (n=13). Additionally, 38 experts from the field of child and adolescent psychiatry were included in the review committee to aid with the development of the child and adolescent section. Of the 110 committee members, 64 general psychiatrists (58.2%) and 23 of 38 child and adolescent psychiatrists (60.5%) responded to the survey.

**Questionnaire**

The KMAP-BP 2014 is a set of expert consensus guidelines modeled after the 2002, 2006, and 2010 KMAP-BP assessments. The questionnaire used in the KMAP-BP 2014 included a majority of the primary questions that were in the KMAP-BP 2010, which had 40 main questions divided into 311 sub-items with a total of 1,151 options, with some modifications. Based on the 2010 survey result, we identified key decision points in the treatment of bipolar disorder and feasible options for management. The major difference between the KMAP-BP 2010 and the KMAP-BP 2014 was the addition of a section for the treatment of children and adolescents with bipolar disorder. Additionally, the chapter that describes insufficient responses to treatment was divided into “partial response” and “nonresponse” sections for manic/hypomanic episodes, and a set of questions regarding mixed features (based on the changes in the *Diagnostic and Statistical Manual of Mental Disorders*, Fifth Edition [DSM-5]) was included in the depressive episode chapter. The 2014 version of the revised KMAP-BP questionnaire had 56 main questions regarding important clinical situations; these were divided into 223 sub-items with a total of 1,799 response options organized into following sections: 1) acute manic episode; 2) acute hypomanic episode; 3) acute major depressive episode; 4) acute mixed episode; 5) rapid cycling; 6) maintenance treatment strategies for bipolar I disorder after acute manic/major depressive episode; 7) maintenance treatment strategies for bipolar II disorder after acute hypomanic/major depressive episode; 8) safety and tolerability issues; 9) treatment strategies for special situations including psychomotor agitation/retardation, violence, cognitive decline, and comorbid mental/physical disorder; 10) geriatric patients; and 11) pediatric patients. A written survey asked about the appropriateness of various treatment strategies and treatment agents commonly used by clinicians as the first-line. We also asked about next steps if there is an inadequate response to initial interventions for each clinical situation.

**Rating scale**

Of the 56 primary questions, 41 inquired about particular clinical cases and addressed the appropriateness of potential treatment options for these cases using a nine-point scale. This scale was based on the Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000; a score of 9 indicated “extremely appropriate”, a score of 7 or 8 indicated “usually appropriate” (first-line), a score of 4–6 indicated “equivocal appropriateness” (second-line), a score of 2 or 3 indicated “usually inappropriate” (a treatment you would rarely use), and a score of 1 indicated “extremely inappropriate” (a treatment you would never use). The remaining 15 questions were open-ended and inquired about the appropriate time period for treatment with a drug before switching strategies, the duration of treatment with antidepressants (ADs) and antipsychotics (APs), and other relevant issues. In their answers, the reviewers were asked to consider ideal treatment options rather than those actually practiced and to choose “q” if they had little experience or did not have available information for a particular question.

**Medication categories**

The medications were categorized as follows: typical APs (eg, haloperidol, chlorpromazine, molindone,
perphenazine, pimozide, etc); atypical APs (AAPs) (eg, aripiprazole [ARI], olanzapine [OZP], quetiapine [QTP], risperidone [RIS], and ziprasidone [ZIP]); other AAPs that were not approved for the treatment of bipolar disorder by the Korean Ministry of Food and Drug Safety (eg, amisulpride, blonanserin, paliperidone, zotepine, and clozapine); mood stabilizers (MSs) (eg, lithium [LIT], valproic acid [VAL], and carbamazepine [CBZP]); and anticonvulsants (eg, gabapentin, levetiracetam, oxcarbazepine, pregabalin, phenytoin, retigabine, topiramate, zonisamide, and lamotrigine [LTG]).

Data analysis

For each option, we first defined the presence or absence of consensus. The rating scores on the nine-point scale were divided into three groups (1–3, 4–6, and 7–9), and a chi-square test was performed to test the distribution of scores across the three ranges of appropriateness. The consensus of the treatment options was defined as a nonrandom distribution of scores by chi-square test ($P \leq 0.05$). Next, we calculated the means, standard deviation, and 95% confidence intervals (CI) for the score of each item, and each treatment option was divided into three categories based on the lowest score of the 95% CI: ≥6.5 for first-line/preferred treatments; <6.5 and ≥3.5 for second-line/reasonable treatments; and <3.5 for third-line/inappropriate treatments. For first-line treatments, the options rated as a 9 by 50% or more of the experts were defined as the treatment of choice (TOC); in other words, the most strongly recommended treatment. The SAS for Windows (version 9.2) was used for the preference ranking and multiple response analyses.

Development of the treatment guidelines and algorithms

Based on the preferred treatment strategies and medications identified by the present survey, the tables and algorithms of the guidelines were determined.

Results

Acute manic episodes

Manic episodes were categorized into three subtypes: euphoric, mixed, and psychotic. The TOC for all subtypes of mania, euphoric (95% CI: 7.8–8.4), mixed (95% CI: 8.3–8.7), and psychotic (95% CI: 8.7–8.9), was the combination of an MS and an AAP (MS plus AAP). The first-line treatments for euphoric and psychotic mania were MS monotherapy (95% CI: 6.8–7.6) and AAP monotherapy (95% CI: 6.7–7.4), respectively (Table 1). The preferred MSs were VAL for euphoric mania (95% CI: 8.0–8.5), mixed mania (95% CI: 8.1–8.6), and psychotic mania (95% CI: 8.0–8.5), and LIT for euphoric mania (95% CI: 7.7–8.3), mixed mania (95% CI: 6.6–7.3), and psychotic mania (95% CI: 7.3–7.9). VAL was the TOC for both euphoric and mixed mania. For all subtypes of mania, the recommended first-line APs were OZP (euphoric mania 95% CI: 7.8–8.3, mixed mania 95% CI: 8.0–8.5, and psychotic mania 95% CI: 8.3–8.7), QTP (euphoric mania 95% CI: 7.8–8.3, mixed mania 95% CI: 8.0–8.4, and psychotic mania 95% CI: 7.8–8.3), RIS (euphoric mania 95% CI: 6.9–7.6, mixed mania 95% CI: 6.8–7.5, and psychotic mania 95% CI: 7.7–8.3), and ARI (euphoric mania 95% CI: 6.7–7.4, mixed mania 95% CI: 6.7–7.4, and psychotic mania 95% CI: 6.8–7.5). OZP was the TOC for both mixed and psychotic mania.

In cases where patients responded poorly to initial MS monotherapy, augmentation with an additional AAP was the TOC for both partial response (95% CI: 8.3–8.7) and nonresponse (95% CI: 8.0–8.5) cases. Switching to an AAP was recommended as a first-line treatment option in a cases

| Table 1 Initial treatment strategies for acute manic/hypomanic episode |
|---------------------------------------------------------------|
| **First-line treatment** | **High second-line treatment** | **Low second-line treatment** |
|--------------------------|-------------------------------|-------------------------------|
| **Euphoric mania**       | MS plus AAP                  | AAP monotherapy               | MS plus TAP                  |
|                         | MS monotherapy               |                               |                             |
| **Mixed mania**          | MS plus AAP                  | MS monotherapy                | MS plus TAP                  |
|                         | MS monotherapy               | AAP monotherapy               | TAP monotherapy              |
| **Psychotic mania**     | MS plus AAP ($^*$)           | MS plus TAP                   | TAP monotherapy              |
|                         | AAP monotherapy              |                               |                             |
| **Hypomania**           | MS monotherapy               | MS plus AAP                   | MS plus TAP                  |
|                         | AAP monotherapy              |                               |                             |

*Note: $^*$Treatment of choice.

Abbreviations: AAP, atypical antipsychotics; MS, mood stabilizer; TAP, typical antipsychotics.
of nonresponse (95% CI: 6.6–7.3), and MS augmentation was the TOC for partial response to initial AAP monotherapy (95% CI: 8.2–8.7). MS augmentation (95% CI: 7.6–8.3) and switching to another AAP (95% CI: 6.9–7.6) were the first-line strategies for nonresponse to initial AAP monotherapy. In cases where the patients responded poorly to an initial combination of MS plus AAP, the addition of another MS (two MSs plus AAP; partial response 95% CI: 7.3–7.9 and nonresponse 95% CI: 7.2–7.9) or another AAP (two AAPs plus MS; partial response 95% CI: 6.8–7.5 and nonresponse 95% CI: 6.8–7.5), and switching from one AAP to another AAP (partial response 95% CI: 7.0–7.7 and nonresponse 95% CI: 7.7–8.2) were the first-line treatment strategies. If the patient did not show a sufficient response to a combination of two MSs plus AAP, the inclusion of an additional AAP (two MSs plus two AAPs) and switching to another AAP were the first-line treatment options regardless of the manic subtype and whether the case was a partial response or nonresponse case (Figure 1).

**Acute hypomanic episodes**

The recommended first-line treatments for a hypomanic episode were MS monotherapy (95% CI: 7.8–8.3) and AAP monotherapy (95% CI: 7.2–7.8; Table 1). The preferred MSs were LIT (95% CI: 7.8–8.3) and VAL (95% CI: 7.9–8.4), and the preferred AAPs were ARI (95% CI: 7.5–8.1), QTP (95% CI: 7.4–8.0), and OZP (95% CI: 7.1–7.7).

In cases where the patients responded poorly to initial MS monotherapy, augmentation with an AAP (partial response 95% CI: 7.5–8.1 and nonresponse 95% CI: 7.6–8.1), switching the MS (partial response 95% CI: 6.6–7.4 and nonresponse 95% CI: 7.3–8.0), a combination of two MSs (partial response 95% CI: 6.5–7.3 and nonresponse 95% CI: 6.6–7.4), and switching the AAP (partial response 95% CI: 6.6–7.2 and nonresponse 95% CI: 7.3–7.9) were recommended as first-line treatment options. If the patient was partially responsive to initial AAP monotherapy, then augmentation with an MS was the first-line treatment strategy (95% CI: 7.8–8.4), and the first-line treatment options for nonresponders were switching the MS (95% CI: 6.8–7.5) or AAP (95% CI: 7.4–8.0) and augmenting the MS (95% CI: 7.6–8.1).

**Acute depressive episodes**

Depressive episodes were categorized into three subtypes: mild, moderate to nonpsychotic severe, and psychotic (Figure 2). The first-line treatment options for acute mild depressive episodes were MS monotherapy (95% CI: 6.8–7.5) and AAP monotherapy (95% CI: 6.5–7.2). For moderate and nonpsychotic severe depressive episodes, MS plus AAP (95% CI: 7.0–7.8) and MS plus AD (95% CI: 6.5–7.3) were recommended as first-line treatment options. For severe depressive episodes with psychotic features, AAP plus MS (95% CI: 7.6–8.2), AAP plus AD (95% CI: 6.5–7.1), AAP

---

**Figure 1** Korean Medication Algorithm for Bipolar Disorder 2014: manic episode.

**Notes:** Electroconvulsive therapy and benzodiazepine can be applied by clinician’s decision at any time. *Treatment of choice. Agents separated by “/” have similar preference. An agent followed by a second agent in parentheses indicates that the first agent has significantly more preference than the second agent.

**Abbreviations:** AAP, atypical antipsychotics; CZP, clozapine; LIT, lithium; mono, monotherapy; MS, mood stabilizer; VAL, valproic acid.
plus LTG (95% CI: 6.9–7.6), AAP plus MS plus LTG (95% CI: 6.5–7.2), AAP plus MS plus AD (95% CI: 7.0–7.6), and AAP plus LTG plus AD (95% CI: 7.0–7.6) were recommended as first-line treatment options (Table 2).

The preferred first-line MSs were VAL (95% CI: 7.2–7.8), LIT (95% CI: 7.2–7.9), and LTG (95% CI: 6.9–7.7). There was not a specific TOC for MSs, but CBZP was a second-line treatment option (95% CI: 5.0–5.8). For severe depression with or without psychotic features, the first-line AAP treatment options were QTP (without psychotic features 95% CI: 7.6–8.1 and with psychotic features 95% CI: 7.5–8.1), ARI (without psychotic features 95% CI: 6.9–7.6 and with psychotic features

Table 2 Initial treatment strategies for acute depressive episode

| Mild                  | First-line treatment | Second-line treatment | Third-line treatment |
|----------------------|----------------------|-----------------------|----------------------|
| MS/AAP monotherapy   | LTG monotherapy      | AAP plus MS/LTG       | ECT                  |
|                      | AAP plus MS/LTG      | MS plus AD/LTG        |                      |
|                      | AAP plus AD          | AAP plus MS plus LTG/AD|                  |
|                      | AAP plus MS plus AD  | MS/AAP/LTG monotherapy|                      |
|                      | AAP plus AD plus LTG | AAP plus LTG          |                      |
|                      | MS plus LTG          | AAP plus AD           |                      |
|                      | MS plus AD/LTG       | MS plus AAP plus AD/LTG|                  |
|                      | AAP plus AD plus LTG | AAP plus AD plus LTG  |                      |
|                      |                      | ECT                   |                      |

| Moderate and nonpsychotic severe depression | First-line treatment | Second-line treatment | Third-line treatment |
|--------------------------------------------|----------------------|-----------------------|----------------------|
| MS plus AAP/AD                             |                      | AAP plus MS/LTG       | ECT                  |
| MS plus AAP/AD                             |                      | AAP plus MS/LTG       |                      |
| MS plus AAP/AD                             |                      | AAP plus AD/LTG       |                      |
| MS plus AAP/AD                             |                      | AAP plus AD           |                      |
| MS plus AAP/AD                             |                      | MS plus AAP plus AD/LTG|                  |
| MS plus AAP/AD                             |                      | AAP plus AD plus LTG  |                      |
| MS plus AAP/AD                             |                      | ECT                   |                      |

| Psychotic severe depression | First-line treatment | Second-line treatment | Third-line treatment |
|-----------------------------|----------------------|-----------------------|----------------------|
| AAP plus MS/AD/LTG          |                      | MS/AAP/LTG monotherapy| ECT                  |
| MS plus AAP plus AD/LTG     |                      | MS plus AD/LTG        |                      |
| AAP plus AD plus LTG        |                      | ECT                   |                      |

Abbreviations: AAP, atypical antipsychotics; AD, antidepressant; ECT, electroconvulsive therapy; LTG, lamotrigine; MS, mood stabilizer.
categorized into three subtypes: mania with mixed features, based on DSM-5 were added. Mixed-features episodes were mood episodes with mixed features and new material. In the present version of the KMAP–BP, questions regard to another first-line AAP (95% CI: 7.1–7.7), or MS (95% CI: 6.9–7.5), and RIS (95% CI: 6.7–7.3). The preferred medications for depression with mixed features were QTP (95% CI: 7.3–7.9), VAL (95% CI: 7.3–7.9), ARI (95% CI: 7.3–7.8), OZP (95% CI: 7.1–7.8), LIT (95% CI: 7.2–7.8), and ARI (95% CI: 7.1–7.6).

Rapid cycling
The recommended initial treatment strategies for patients not currently under medication were AAP monotherapy (95% CI: 6.5–7.2) or MS plus AAP (95% CI: 7.7–8.4) for those in a manic state, and AAP monotherapy (95% CI: 6.5–7.2), MS plus AAP (95% CI: 7.3–8.0), MS plus LTG (95% CI: 6.5–7.4), or AAP plus LTG (95% CI: 6.5–7.4) for those in a depressed state. For patients with rapid cycling, current manic episodes, or an insufficient response to MS monotherapy, the addition of an AAP was the TOC (95% CI: 7.8–8.4), and the addition of another first-line MS (95% CI: 7.1–7.7) was the first-line treatment option. If a patient was in a depressive state during rapid cycling and did not sufficiently respond to MS plus AD, the addition of an MS (95% CI: 7.0–7.6), an AAP (95% CI: 7.0–7.6), or LTG (95% CI: 6.9–7.7) and switching the MS to another first-line MS (95% CI: 6.6–7.2) were recommended. The recommended medications for a patient in a manic state during rapid cycling were VAL (95% CI: 7.8–8.3), QTP (95% CI: 7.5–8.0), OZP (95% CI: 7.3–7.8), LIT (95% CI: 6.8–7.4), and ARI (95% CI: 6.6–7.2). The recommended medications for a patient in a depressive state during rapid cycling were QTP (95% CI: 7.4–8.0), VAL (95% CI: 7.2–7.8), OZP (95% CI: 7.1–7.7), LTG (95% CI: 6.9–7.5), ARI (95% CI: 6.8–7.4), and LIT (95% CI: 6.8–7.4).

Maintenance treatment
The recommended first-line maintenance strategies for patients following a manic episode were MS plus AAP (95% CI: 7.7–8.2), MS monotherapy (95% CI: 7.2–7.8),
**Table 3** Next step treatment strategies when initial treatment for bipolar depression was inadequate

|                      | First-line strategies            | Second-line strategies | Third-line strategies |
|----------------------|----------------------------------|------------------------|-----------------------|
| **MS monotherapy**   |                                  |                        |                       |
| No response          | Add AAP                          | Change to LTG          | Add thyroid hormone   |
|                      | Add LTG                          | Change to another MS   |                       |
|                      |                                   | Add AD                 |                       |
|                      |                                   | Add MS                 |                       |
|                      |                                   | Add stimulant          |                       |
|                      |                                   | Add TAP                |                       |
| Partial response     | Add AAP                          | Add AD                 |                        |
|                      | Add LTG                          | Add MS                 |                        |
|                      | Add MS                           | Add stimulant          |                        |
| **AAP monotherapy**  |                                  |                        |                       |
| No response          | Add LTG                          | Change AAP             | Change to TAP          |
|                      | Add MS                           | Add AD                 | Add thyroid hormone    |
|                      | Change to another AAP            | Add stimulant          |                       |
| Partial response     | Add MS                           | Change to another AAP  |                        |
|                      | Add LTG                          | Add AD                 |                        |
|                      | Add stimulant                    | Add TAP                |                        |
| **LTG monotherapy**  |                                  |                        |                       |
| Inadequate response  | Add AAP                          | Add AD                 |                        |
|                      | Add MS                           | Change to MS           | Add thyroid hormone    |
|                      | Add stimulant                    | Add TAP                |                       |
| **MS plus AP combination** |                      |                        |                       |
| No response          | Add LTG                          | Add AD                 | Add TAP                |
|                      | Change to another MS             | Add MS                 |                        |
|                      | Change to LTG                    | Add AAP                |                        |
|                      | Add stimulant                    | Add AP                 |                        |
|                      | Add TAP                          | Add AD                 |                        |
| Partial response     | Add LTG                          | Add AD                 |                        |
|                      | Add AAP                          | Change to LTG          |                        |
|                      | Add MS                           | Change to another MS   | Add TAP                |
|                      | Add stimulant                    | Add TAP                |                        |
| **MS plus AD combination** |                      |                        |                       |
| No response          | Add AAP                          | Change to another AD   | Add thyroid hormone    |
|                      | Add LTG                          | Add MS                 |                        |
|                      | Change to LTG                    | Add AD                 |                        |
|                      | Change to another MS             | Add stimulant          |                        |
|                      | Add TAP                          | Add AD                 |                        |
| Partial response     | Add AAP                          | Add MS                 |                        |
|                      | Add LTG                          | Change to LTG          | Add TAP                |
|                      | Change to another MS             | Change other AD        |                        |
|                      | Add AD                           | Add AD                 |                        |
|                      | Add stimulant                    | Add TAP                |                        |
| **AP plus LTG combination** |                      |                        |                       |
| Inadequate response  | Add MS                           | Add AAP                | Add TAP                |
|                      | Add AD                           | Add stimulant          | Add thyroid hormone    |

**Abbreviations:** AP, antipsychotics; AAP, atypical AP; AD, antidepressant; LTG, lamotrigine; MS, mood stabilizer; TAP, typical AP.

and AAP monotherapy (95% CI: 7.0–7.6). If MS plus AAP was selected as the first-line treatment, then the recommended AAPs were QTP (95% CI: 7.6–8.1), ARI (95% CI: 7.5–8.0), and OZP (95% CI: 7.2–7.7), and the preferred AAP monotherapies were QTP (95% CI: 7.7–8.2), OZP (95% CI: 7.4–8.0), and ARI (95% CI: 7.4–8.0). The recommended AAP maintenance period following remission was 14–43 weeks, but 67.2% of the respondents recommended “maintaining the initial AAP as long as possible”.


The recommended first-line maintenance strategies for patients following a depressive episode were MS plus AAP (95% CI: 7.3–7.8), MS plus LTG (95% CI: 7.1–7.8), AAP plus LTG (95% CI: 7.0–7.6), MS monotherapy (95% CI: 6.8–7.4), LTG monotherapy (95% CI: 6.5–7.1), and MS plus AAP plus LTG (95% CI: 6.5–7.2). When an AD was necessary, bupropion (95% CI: 6.8–7.6), topiramate (95% CI: 4.0–5.4), and metformin (95% CI: 4.0–5.4) were second-line treatment strategies. In obese or overweight patients, ARI (95% CI: 6.8–7.7) was the first-line treatment strategy, and LTG (95% CI: 5.9–6.6) and ZIP (95% CI: 6.0–7.0) were second-line options. In patients with signs or symptoms of hyperprolactinemia, including amenorrhea or galactorrhea, switching to an AAP with a low risk for hyperprolactinemia was the first-line treatment option, and a dose reduction of the current medication was the second-line treatment option. If benign skin rashes appeared during LTG treatment, reducing the dose and close monitoring were the first-line treatment options, and a discontinuation of LTG was the second-line treatment option.

In patients with bipolar disorder who also had cardiovascular, diabetic, or hepatic comorbidities, ARI was the first-line treatment strategy (cardiovascular disease 95% CI: 6.5–7.3, diabetes 95% CI: 7.1–7.8, and hepatic disease 95% CI: 6.7–7.3), whereas LIT was another first-line option for hepatic comorbidities (95% CI: 6.8–7.6). In cases of bipolar disorder with a renal comorbidity, ARI (95% CI: 6.7–7.4), VAL (95% CI: 6.6–7.3), and QTP (95% CI: 6.5–7.2) were the preferred treatment options. VAL was recommended as the first-line treatment (95% CI: 7.2–7.8) for patients with bipolar disorder who had comorbid cerebrovascular diseases.

Children and adolescents
The first-line treatment strategy for manic episodes in children and adolescents with bipolar disorder was MS plus AAP (children 95% CI: 7.0–8.2 and adolescents 95% CI: 6.8–8.2). For children, AAP monotherapy was a first-line treatment strategy (95% CI: 6.6–7.7) but only a second-line option for adolescents (95% CI: 6.3–7.6; Table 4). Among AAPS, ARI (children 95% CI: 7.5–8.3 and adolescents 95% CI: 7.5–8.3), RIS (children 95% CI: 7.4–8.1 and adolescents 95% CI: 7.8–8.4), and QTP (children 95% CI: 7.0–8.0 and adolescents 95% CI: 7.2–8.1) were first-line treatment options, and VAL (children 95% CI: 6.9–8.0 and adolescents 95% CI: 7.3–8.3) was the first-line MS for both children and adolescents. There was no consensus regarding first-line treatment for depressives episodes in children and adolescents with bipolar disorder (Table 4), but in cases where pharmacological treatment was necessary, ARI (95% CI: 7.6–8.5) and QTP (95% CI: 6.6–8.0) were recommended as first-line treatment options for children, and LTG (95% CI: 6.5–8.2), VAL (95% CI: 6.6–7.6), ARI (95% CI: 7.5–8.3), and QTP (95% CI: 6.8–8.0) were recommended as first-line options for adolescents. No consensus regarding a first-line treatment strategy for children and adolescents with depressive episodes and at high risk for bipolar disorder (eg, family history of bipolar disorder) was reached.

Safety, tolerability, and medical comorbidities
When the weight of a patient significantly increased due to pharmacotherapy, the primary recommendations included behavioral and diet modifications and switching to another AAP with a low risk of weight gain. If additional medications were needed to counteract weight gain, bupropion (95% CI: 4.5–5.6), topiramate (95% CI: 4.0–5.4), and metformin (95% CI: 4.0–5.4) were second-line treatment strategies. In obese or overweight patients, ARI (95% CI: 6.8–7.7) was the first-line treatment strategy, and LTG (95% CI: 5.9–6.6) and ZIP (95% CI: 6.0–7.0) were second-line options. In patients with signs or symptoms of hyperprolactinemia, including amenorrhea or galactorrhea, switching to an AAP with a low risk for hyperprolactinemia was the first-line treatment option, and a dose reduction of the current medication was the second-line treatment option. If benign skin rashes appeared during LTG treatment, reducing the dose and close monitoring were the first-line treatment options, and a discontinuation of LTG was the second-line treatment option.
For geriatric bipolar patients with acute manic episodes, AAP monotherapy (95% CI: 7.1–7.8), MS monotherapy (95% CI: 7.1–7.7), and MS plus AAP (95% CI: 7.0–7.8) were recommended as first-line treatment strategies. AAP plus MS (95% CI: 6.7–7.4) and AAP monotherapy (95% CI: 6.7–7.3) were the first-line treatment strategies for patients with acute depressive episodes (Table 5). The recommended first-line MSs for acute manic episodes were VAL (95% CI: 7.4–7.9) and LIT (95% CI: 6.6–7.3), and the recommended first-line AAPs were ARI (95% CI: 7.3–7.9), QTP (95% CI: 7.1–7.7), and OZP (95% CI: 7.4–7.6). The first-line MSs for patients with acute depressive episodes were LTG (95% CI: 6.8–7.5) and VAL (95% CI: 6.4–7.0); the first-line AAPs were ARI (95% CI: 7.2–7.9), QTP (95% CI: 7.2–7.8), and OZP (95% CI: 6.7–7.3); and the preferred ADs were (es) citalopram (95% CI: 7.2–7.8), bupropion (95% CI: 6.9–7.6), and sertraline (95% CI: 6.8–7.4). In cases where dementia...
was comorbid with bipolar disorder, ARI (95% CI: 7.0–7.7) and QTP (95% CI: 6.7–7.3) were recommended as first-line treatment options.

Discussion

Treatment strategies for mania

The most preferred initial treatment strategy for mania, regardless of type, was MS plus AAP; the same recommendation was made in the KMAP-BP 2010. However, while the KMAP-BP 2014 recommended AAP monotherapy as a first-line strategy for psychotic mania, AAPs were considered to be a second-line strategy in the KMAP-BP 2010. This finding reflects the recent accumulation of evidence and data supporting AAP monotherapy as a viable treatment strategy for bipolar patients with psychotic mania.

Because mania was categorized by symptom subtype in the KMAP-BP 2014, the present recommendations could not be directly compared with other guidelines that did not classify mania into subtypes. However, the present recommendation is in agreement with the Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines, which suggest LIT, VAL, AAP monotherapy, or a combination of two of these drugs as first-line treatments. The guidelines for the biological treatment of bipolar disorder from the World Federation of Societies for Biological Psychiatry (WFSBP) recommend monotherapy with ARI, RIS, ZIP, VAL, and LIT as first-line treatment options. When there is no response to monotherapy after 2 weeks or a partial response after 5 weeks following monotherapy in patients with severe mania, the WFSBP guidelines recommend the combination of two medications. Although the WFSBP guidelines stress that there is insufficient unambiguous evidence supporting combination therapy as a general first-line treatment for mania, the present findings demonstrate greater efficacy of combination treatment. This result is supported by a previous meta-analysis and the widespread use of combination treatment in clinical practice.

According to the present guidelines, in the absence of a response to initial treatment, the appropriate next-step treatment strategies include AAP plus MS and switching to another first-line medication in the case of a partial response. If the response to treatment with MS plus AAP was inadequate, the addition of an AAP or MS, or switching from the original AAP to another AAP was the next-step strategy. This finding is different from that of the KMAP-BP 2010, which recommended the addition of another MS following an inadequate response to treatment with MS plus AAP. The KMAP-BP 2014 recommends replacing the current medication with another first-line medication, which is in agreement with the CANMAT guidelines. Moreover, the KMAP-BP 2014 allows for a triple combination of pharmacological agents (two AAPS plus MS or AAP plus two MSs), although this treatment strategy is not supported by solid evidence at this stage. This finding may have been influenced by the Korean medical insurance system, which does not approve of the off-label use of pharmacotherapies such as paliperidone, oxcarbazepine, or tamoxifen that may be recommended in foreign guidelines.

Treatment strategies for depression

The KMAP-BP 2010 did not identify a TOC for the initial treatment of acute bipolar depression, which underscores the difficulties and controversies involved in the selection of a treatment strategy for this type of bipolar episode. The KMAP-BP 2014 includes several changes from the previous version. The KMAP-BP 2010 recommended monotherapy with MS or LTG for mild depression and combination therapy with MS plus AAP plus AD for severe depression without psychotic feature as first-line treatment options. However, in the KMAP-BP 2014, AAPs were included as an appropriate monotherapy for mild depression, and the combination of two medications from three types (AAP plus LTG) was added as a first-line treatment for moderate to severe depression. Additionally, LTG was added as a first-line option for the treatment of severe depression with psychotic features.

The most evident update in the KMAP-BP 2014 is the increased preference for the use of AAP monotherapy to treat moderate to severe depression, which is not surprising based on evidence from a number of recent studies, and various treatment guidelines. Another notable change in the KMAP-BP 2014 is the strong preference for ARI and LTG for the treatment of moderate to severe depression. In recent meta-analyses, ARI monotherapy and LTG monotherapy were not found to be superior to placebo. Furthermore, ARI was categorized as evidence category “E” in the WFSBP guidelines, meaning that there was opposing evidence, and as “not recommended” in the CANMAT guidelines. However, another meta-analysis suggested that ARI monotherapy could be effective for the treatment of acute depression because the combined data from two negative studies revealed a significant effect.

The high preferences for ARI and LTG in the KMAP-BP 2014 are likely derived from tolerability issues. Clinically
significant weight gain, metabolic disruption, and sedation are significant limitations of the use of OZP and QTP,34 and the risk estimates for somnolence, sedation, and significant weight gain following treatment with OZP and QTP for bipolar depression were significantly higher than those with placebo.35 Accordingly, these side effects may hamper the clinical use of these pharmacological agents.36 Moreover, the consensus in the present study was that the combination of an AAP (QTP, OZP, or ARI) with an MS was appropriate for the treatment of moderate to severe depression. Although a small randomized controlled trial did not find a significant effect of this type of treatment compared with placebo,37 some open-label trials have demonstrated the benefit of adjunctive ARI treatment for patients with bipolar depression.38,39 LTG was included in evidence category “B”, ie, limited positive evidence was available, in a previous controlled study5 and is a first-line treatment option according to CANMAT guidelines12 based on a meta-analysis of individual patient data that supported the efficacy of LTG treatment.40

Treatment strategies for mixed-features episodes and rapid cycling

The first-line treatment options for mixed-features episodes and rapid cycling were MS plus AAP and AAP monotherapy. LTG was the preferred treatment for depressed states during rapid cycling and for depression with mixed features. Existing treatment guidelines typically do not recommend a specific treatment for mixed states or rapid cycling, and the pharmacological treatment options are limited and mostly based on findings from subanalyses or post hoc analyses. Therefore, there is no clear consensus regarding optimal pharmacological management for mixed states or rapid cycling, and the selection of a treatment strategy is usually based on individual factors such as safety and tolerability.41 However, it is well known that patients with mixed-state episodes and/or rapid cycling exhibit a poorer pharmacological response than do patients with pure mood episodes, and that combination therapy is typically required.42-44 The KMAP-BP 201031 did not evaluate treatment strategies for mixed-features episodes, but the most-recommended treatment strategies for rapid cycling were MS plus AAP and the combination of two MSs. Because OZP, QTP, and ARI are effective for the treatment of acute bipolar episodes45-50 and ARI and OZP show promise for the maintenance of rapid cyclers,50,51 there was an increased preference for the use of AAPs in the KMAP-BP 2014.

Treatment strategies for maintenance therapy

Following a manic episode, maintenance therapy with MS plus AAP was the most-preferred strategy, although monotherapy with an MS or AAP was also regarded as a first-line treatment strategy for the prevention of a recurrent episode. Unlike the KMAP-BP 2010,21 AAP monotherapy was included as a first-line treatment option in the KMAP-BP 2014. Moreover, the KMAP-BP 2014 recommends maintaining AAP monotherapy after remission from an acute episode, whereas the KMAP-BP 2010 recommended tapering the use of AAPs after recovery in conjunction with AAP or MS maintenance as a first-line treatment option. These changes from the KMAP-BP 2010 indicate the emerging preference for AAPs for maintenance treatment, as do other recent treatment guidelines.4,12

The KMAP-BP 2014 recommends MS plus LTG, AAP plus LTG, LTG monotherapy, and MS plus AAP plus LTG as first-line maintenance treatment options for depressive episodes. Thus, it appears that the preference of experts for the inclusion of LTG in maintenance therapies following a depressive episode is increasing compared with that seen in the KMAP-BP 2010. Recent Korean studies investigating bipolar disorder maintenance and safety52,53 appear to have played a role in this change.

Special considerations

The KMAP-BP 2014 recommends ARI as a first-line treatment option and ZIP as a second-line treatment option for obese or overweight patients. Although the metabolic profile of ARI appears to be benign, this drug is not free of complications such as significant weight gain. A recent review found that the mean weight change following ARI treatment was not significantly different from that following placebo, but there was a clinically significant (≥7%) increase in weight.54 On the other hand, ZIP is relatively weight neutral,55 and, thus, the present findings of the KMAP-BP 2014 may be based on studies showing no significant difference between ZIP plus MS and placebo for the treatment of bipolar depression,56 the inferiority of ZIP monotherapy compared with haloperidol,57 and the absence of a significant difference between ZIP as an add-on therapy and placebo for patients with bipolar mania.58 Although ZIP is recommended as a first-line treatment option for acute mania6,12 and maintenance,12 experts in the present study prefer ARI to ZIP for obese or overweight patients due to its overall effectiveness; this agrees with the WFSBP guidelines for long-term treatment.4
The preferred treatment strategies for pediatric bipolar disorder with mania were MS plus AAP and AAP monotherapy. There was no consensus regarding a first-line treatment for depressive episodes. These findings make sense because most randomized controlled trials investigating pediatric bipolar patients assessed the acute treatment of manic symptoms. The Child and Adolescent Bipolar Foundation recommends LIT, VAL, CBZP, OZP, QTP, or RIS monotherapy for bipolar I manic/mixed episodes, and the American Academy of Child and Adolescent Psychiatry recommends LIT, VAL, and AAPS for the treatment of bipolar I mania. In the KMAP-BP 2014, the recommended medications for the treatment of mania in children are ARI, RIS, QTP, and VAL, whereas OZP and LIT were less preferred than for adult patients. The United States Food and Drug Administration approved ARI, RIS, and QTP for the treatment of acute mania in children and adolescents aged 10 years or older based on several trials. However, OZP was approved for children aged 13 years and older, and this may have affected the results. The risk of adverse metabolic events should also be considered as another possible cause of the low preference for OZP. Additionally, the presentation of mania in youths with irritability, rage, and labile mood may also lead to a greater preference for VAL over LIT.

Limitations of the KMAP-BP 2014

A major limitation of the present study is that it was based on the consensus of Korean experts rather than on experimental evidence. Thus, some viable treatment strategies may not have been rated as first-line options despite evidence demonstrating their effectiveness. However, most of these experimental data are derived from randomized controlled trials and cannot reflect the complexity of various real-life clinical situations, which suggests that there may be some discrepancies between the findings of randomized controlled trials and the intricacies of real-world practice. Accordingly, the KMAP-BP 2014 suggests a variety of treatment options based on expert recommendations that reflect the unique characteristics of the Korean health care environment, clinical experience, and experimental evidence. The KMAP-BP assessments also reveal the updated recommendations of Korean experts for the treatment of bipolar patients with revisions every 4 years. As this project has proceeded, the expert consensus has changed for many treatment strategies, and the options and numbers of choices for treatment have increased. Additionally, because the KMAP-BP 2014 contains discussions regarding the safety of various medications and the consideration of special populations such as children, adolescents, and elderly patients, it will be effective for dealing with diverse challenging situations in real-world clinical practice.

Another limitation of the present study is that the review committee may have been too small to reach a valid consensus. Only 110 experts were engaged for the adult section, and only 38 experts for the children and adolescents section. However, because there are only 3,750 psychiatrists in South Korea and the membership of the Korean Society for Affective Disorders is 258, a sample of 148 psychiatrists may not be sufficient. Final, this algorithm does not include the dosage of medications or the nature of psychosocial interventions, which require further research. Moreover, novel pharmacological agents such as lurasidone, asenapine, and cariprazine, which are supported by increasing amounts of evidence and have been recommended in recent foreign guidelines, were excluded from this algorithm because they were not available in South Korea. Hence, this guideline could be limited in its use for clinicians in another countries. However, there might be countries in which newer agents are not available; therefore, this guideline could be informative in some countries.

In summary, the pharmacological treatment strategies supported by the KMAP-BP 2014 have markedly changed from previous versions. Most notably, the preferences for AAPSs and LTG for the management of bipolar disorder have increased, and the current treatment options are in concordance with various other recent guidelines for bipolar disorder treatment. To our knowledge, the KMAP-BP 2014 is the only set of treatment guidelines in Asia that has been updated and revised every 4 years since 2002. Thus, despite the limitations of this expert consensus, it is expected that the KMAP-BP 2014 will provide clinicians with a wealth of information regarding appropriate strategies for treating patients with bipolar disorder.

Acknowledgments

The present manuscript is a secondary publication of our group’s papers which were already published in the Korean language. Though we have already published the papers in Korea, we decided to present and share the results with the experts who speak English according to conditions for acceptable secondary publications as stated in Uniform Requirements for Manuscripts Submitted to Biomedical Journals by International Committee of Medical Journal Editors. The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/doSMpe.
Author contributions
All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References
1. No authors listed. Treatment of bipolar disorder. The Expert Consensus Panel for Bipolar Disorder. J Clin Psychiatry. 1996;57 Suppl 12A:3–88.
2. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med. 2000;Spec No:1–104.
3. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 Suppl):1–50.
4. Gruenz H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219.
5. Gruenz H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81–109.
6. Gruenz H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10(2):85–116.
7. Gruenz H, Kasper S, Goodwin G, Bowden C, Möller HJ; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry. 2004;5(3):120–135.
8. Gruenz H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry. 2003;4(1):5–13.
9. Gruenz H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry. 2002;3(3):115–124.
10. Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003;17(2):149–173; discussion 147.
11. Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition – recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346–388.
12. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.
13. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225–255.
14. Yatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;8(6):721–739.
15. Yatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7 Suppl 3:5–69.
16. Bakh WM, Shin YC, Jon DI, et al. Korean Medication Algorithm for Bipolar Disorder (I). Korean J Psychopharmacol. 2002;13:205–221.
17. Kim CH, Min KJ, Shin YC, et al. Feasibility of Korean Medication Algorithm for Bipolar Disorder (I): Global assessment. Korean J Psychopharmacol. 2005;16:225–233.
18. Shin YC, Bakh WM, Kim CH, et al. Feasibility of Korean Medication Algorithm for Bipolar Disorder (II): Choice of medications. Korean J Psychopharmacol. 2005;16:285–291.
19. Jon DI, Bakh WM, Shin YC, et al. Feasibility of Korean Medication Algorithm for Bipolar Disorder (III): Treatment response and tolerability. Korean J Psychopharmacol. 2005;16:292–300.
20. Jon DI, Bakh WM, Yoon BH, et al. Revised Korean medication algorithm for bipolar disorder. World J Biol Psychiatry. 2009;10(4 Pt 3):846–855.
21. Shin YC, Min KJ, Yoon BH, et al. Korean medication algorithm for bipolar disorder: second revision. Asia Pac Psychiatry. 2013;5(4):301–308.
22. Seok Seo J, Rim Song H, Bin Lee H, et al. The Korean Medication Algorithm for Depressive Disorder: second revision. J Affect Disord. 2014;167:312–321.
23. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs monotherapy. Acta Psychiatr Scand. 2007;115(1):12–20.
24. Lee SM, Shin IH, Woo YS, Jun TY, Bakh WM. [A trend of medication prescription pattern for outpatients with bipolar disorder in a university hospital: focusing on atypical antipsychotics]. Korean J Psychopharmacol. 2014;25(3):124–133. Korean.
25. Cha JM, Shin IH, Woo YS, Jun TY, Bakh WM. A trend of drug use in inpatients with bipolar disorder: comparing 2009–2012 with 1998–2001 in one university hospital. Korean J Psychopharmacol. 2014;25(3):114–123.
26. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(1):1079–1088.
27. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351–1360.
28. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600–609.
29. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163–174.
30. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol. 2010;13(1):5–14.
31. Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014;47(2):43–52.
32. Fountoulakis KN, Vieta E, Schmidt F. Aripiprazole monotherapy in patients with bipolar I or II depression: a double-blind, placebo-controlled study. World J Biol Psychiatry. 2007;8(3):224–231.
33. Vieta E, Calabrese J, Sánchez-Moreno J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination therapy in the treatment of acute bipolar I depression. J Clin Psychiatry. 2006;67(1):11–17.
34. Calabrese JR, Keck PE Jr, Macfadden W, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression. Am J Psychiatry. 2006;163(1):11–17.
35. Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014;47(2):43–52.
36. Fountoulakis KN, Vieta E, Schmidt F. Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis. J Affect Disord. 2011;133(3):361–370.
37. Vieta E, Valenti M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013;27(7):515–529.
46. De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: a randomized review and meta-analysis. J Psychopharmacol. 2012;26(5):603–617.

47. Quante A, Zeugmann S, Luborowski A, et al. Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study. Hum Psychopharmacol. 2010;25(2):126–132.

48. Mazza M, Squillaciotti MR, Pecora RD, Janiri L, Bria P. Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial. Expert Opin Pharmacother. 2009;10(18):3145–3149.

49. Dunning RT, Stan VA, Chriki LS, Filkowski MM, Ghaemi SN. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression. J Affect Disord. 2008;110(1–2):70–74.

50. Gillies JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194(1):4–9.

51. Vieta E, Valenti M. Mixed states in DSM-5: implications for clinical care, and education. J Affect Disord. 2013;148(1):28–36.

52. Yildiz A, Vieta E, Tohen M, Baldessarini RJ. Factors modifying drug and placebo responses in randomized trials for bipolar mania. Int J Neuropsychopharmacol. 2011;14(7):863–875.

53. González-Pinto A, Aldama A, Mosquera F, González Gómez C. Epidemiology, diagnosis and management of mixed mania. CNS Drugs. 2007;21(8):611–626.

54. Fountoulakis KN, Kontis D, Gonda X, Yatham LN. A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Disord. 2013;15(2):115–137.

55. Baldessarini RJ, Hennen J, Wilson M, et al. Olanzapine versus placebo in rapid-cycling bipolar I disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2007;9(4):413–425.

56. Muzina DJ, Monah C, Eudicone JM, et al. Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Int J Clin Pract. 2008;62(5):679–687.

57. Woo YS, Bahk WM, Pae CU, et al. Observational study to evaluate the clinical benefit of lamotrigine add-on therapy in bipolar patients in a naturalistic treatment setting. Asia Pac Psychiatry. 2014;6(3):334–341.

58. Woo YS, Bahk WM, Jon DI, et al. Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(7):1147–1152.

59. McIntyre RS. Aripiprazole for the maintenance treatment of bipolar I disorder: A review. Clin Ther. 2010;32 Suppl 1:S32–S38.

60. Kemp DE, Karayal ON, Calabrese JR, et al. Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles. Eur Neuropsychopharmacol. 2012;22(2):123–131.

61. Sachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1413–1422.

62. Warrington L, Lombardo I, Loebl A, Ice K. Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. CNS Drugs. 2007;21(10):835–849.

63. Weisler R, Warrington L, Dunn J. Adjunctive ziprasidone in bipolar mania: Short- and long-term data. Biol Psychiatry. 2004;55:43s–43s.

64. Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(3):213–235.

65. McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):107–125.

66. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70(10):1441–1451.

67. Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70(10):1441–1451.

68. Pathak S, Findling RL, Earley WR, Acevedo LD, Stankowski J, Delbello MP. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74(1):e100–e109.

69. Miller L, Barnett S. Mood lability and bipolar disorder in children and adolescents. Int Rev Psychiatry. 2008;20(2):171–176.

70. Woo YS, Wang HR, Bahk WM, Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:1521–1529.